呼吸感染性疾病诊治年度进展2023  

Annual updates of pulmonary infectious diseases in 2023

作　　者：张国良 瞿介明 Zhang Guoliang;Qu Jieming(Department of Pulmonary and Critical Care Medicine,Rui-jin Hospital,Shanghai Jiaotong University School of Medicine,Key Laboratory of Emergency Prevention,Diagnosis and Treatment of Respiratory Infectious Diseases,Institute of Respiratory Diseases,School of Medicine,Shanghai Jiaotong University,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院呼吸与危重症医学科、上海市呼吸传染病应急防控与诊治重点实验室、上海交通大学医学院呼吸病研究所,上海200025

出　　处：《中华结核和呼吸杂志》2024年第2期141-146,共6页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：上海市重点专科项目(shslczdzk02202);上海市呼吸传染病应急防控与诊治重点实验室项目(20dz2261100)。

摘　　要：2023年,各类肺部感染性疾病仍在危害人群生命健康。呼吸感染性疾病的诊治面临诸多挑战,包括肺炎常见病原菌的耐药性持续增加、结核病的发病率上升且防治进程放缓、病毒流行导致真菌感染性疾病增加等。过去一年,在致病机制认识、检测技术革新、新型抗菌与抗病毒药物的开发、疫苗的基础与临床研究、预防和康复手段等领域有众多重磅研究成果发表。本文详细回顾和总结了呼吸感染性疾病领域在2023年度发表的重要研究成果,为未来的研究和实践提供参考。In 2023,a range of pulmonary infectious diseases remain a significant public health concern.Meanwhile,the growing problem of antibiotic resistance,rising tuberculosis cases with lagging control measures,and increased susceptibility to fungal pneumonia after viral infections,have complicated the diagnosis and treatment of respiratory infectious diseases.Despite these challenges,the year saw several significant research achievements in this field.Key advances include a deeper understanding of disease pathogenesis,improvements in pathogen detection technologies,the development of innovative antiviral and antibacterial drugs,progress in vaccine research,and advances in pulmonary rehabilitation methods.This review provided a concise summary of these key findings in 2023,with the aim of providing insights for future research and healthcare initiatives.

关 键 词：感染性疾病 抗病毒药物 致病机制 重要研究成果 康复手段 常见病原菌 病毒流行 技术革新 

分 类 号：R56[医药卫生—呼吸系统]